Catalyst Pharmaceuticals, Inc.
Index- P/E16.97 EPS (ttm)0.42 Insider Own0.70% Shs Outstand102.78M Perf Week6.33%
Market Cap720.47M Forward P/E8.78 EPS next Y0.80 Insider Trans-17.35% Shs Float95.03M Perf Month0.43%
Income45.10M PEG- EPS next Q0.19 Inst Own71.60% Short Float10.28% Perf Quarter-14.84%
Sales153.70M P/S4.69 EPS this Y-48.10% Inst Trans7.32% Short Ratio8.60 Perf Half Y2.47%
Book/sh2.14 P/B3.30 EPS next Y19.29% ROA19.70% Target Price11.60 Perf Year21.93%
Cash/sh1.94 P/C3.64 EPS next 5Y- ROE22.10% 52W Range4.81 - 8.65 Perf YTD4.28%
Dividend- P/FCF- EPS past 5Y29.80% ROI19.00% 52W High-15.50% Beta1.26
Dividend %- Quick Ratio9.30 Sales past 5Y- Gross Margin85.00% 52W Low51.87% ATR0.32
Employees76 Current Ratio9.60 Sales Q/Q42.70% Oper. Margin39.10% RSI (14)59.30 Volatility4.65% 4.67%
OptionableYes Debt/Eq0.00 EPS Q/Q69.10% Profit Margin29.30% Rel Volume0.68 Prev Close7.06
ShortableYes LT Debt/Eq0.00 EarningsMay 10 AMC Payout0.00% Avg Volume1.14M Price7.30
Recom2.00 SMA208.04% SMA503.23% SMA2006.15% Volume556,581 Change3.47%
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-07-18Resumed Piper Jaffray Overweight
Oct-05-16Upgrade Piper Jaffray Neutral → Overweight
Apr-26-16Downgrade Piper Jaffray Overweight → Neutral $6 → $1
Sep-30-14Reiterated ROTH Capital Buy $5 → $6
Sep-16-14Reiterated ROTH Capital Buy $3.50 → $5
Sep-15-14Reiterated H.C. Wainwright Buy $5 → $13
Oct-21-13Reiterated Aegis Capital Buy $4 → $5.50
Sep-24-13Initiated Maxim Group Buy $4
Sep-06-13Reiterated Aegis Capital Buy $3.50 → $4
Apr-18-13Initiated Aegis Capital Buy $2.50
Aug-27-12Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $3.70
Oct-01-09Upgrade Merriman Sell → Neutral
May-29-09Downgrade Merriman Curhan Ford Buy → Sell
May-29-09Downgrade Hapoalim Neutral → Underperform
Dec-15-08Initiated Merriman Curhan Ford Buy
Nov-28-07Initiated Rodman & Renshaw Mkt Outperform $9
Jan-31-07Initiated Stifel Nicolaus Buy $9
Jan-05-07Initiated First Albany Buy $10
Jun-25-22 08:15AM  
Jun-09-22 11:30AM  
Jun-04-22 11:07AM  
May-17-22 08:03AM  
May-11-22 06:05AM  
May-10-22 05:25PM  
May-09-22 05:45PM  
Apr-25-22 08:03AM  
Apr-05-22 06:41PM  
Mar-29-22 05:15PM  
Mar-16-22 05:45PM  
Mar-11-22 08:03AM  
Mar-09-22 03:00PM  
Mar-08-22 08:03AM  
Mar-03-22 09:20AM  
Mar-02-22 08:03AM  
Feb-28-22 10:00AM  
Feb-24-22 08:03AM  
Feb-17-22 08:03AM  
Feb-15-22 10:41AM  
Feb-11-22 08:50AM  
Feb-10-22 10:00AM  
Feb-08-22 09:49AM  
Feb-07-22 08:03AM  
Feb-03-22 08:03AM  
Jan-28-22 01:46PM  
Jan-16-22 07:05AM  
Jan-10-22 08:03AM  
Jan-05-22 07:25AM  
Jan-04-22 07:30AM  
Dec-20-21 06:23AM  
Dec-06-21 07:00AM  
Dec-02-21 05:13AM  
Nov-15-21 04:15PM  
Nov-09-21 06:35PM  
Nov-04-21 08:50AM  
Nov-02-21 03:02PM  
Oct-25-21 08:03AM  
Oct-18-21 08:24AM  
Oct-12-21 08:50AM  
Oct-08-21 07:21AM  
Sep-30-21 12:08PM  
Sep-17-21 08:03AM  
Sep-10-21 08:03AM  
Sep-08-21 11:30AM  
Aug-16-21 08:03AM  
Aug-09-21 06:55PM  
Aug-02-21 03:01PM  
Jul-26-21 08:03AM  
Jul-23-21 04:03AM  
Jul-19-21 08:03AM  
Jul-06-21 08:03AM  
Jun-29-21 08:03AM  
Jun-28-21 04:30PM  
Jun-16-21 02:38AM  
Jun-09-21 11:30AM  
Jun-03-21 03:09PM  
May-19-21 08:03AM  
May-11-21 06:30AM  
May-10-21 07:05PM  
May-08-21 06:12AM  
May-03-21 03:01PM  
Apr-14-21 11:30AM  
Apr-05-21 01:03AM  
Mar-22-21 08:03AM  
Mar-21-21 04:42AM  
Mar-18-21 06:02PM  
Mar-16-21 10:38AM  
Mar-15-21 06:45PM  
Mar-08-21 12:30PM  
Mar-04-21 11:00AM  
Feb-22-21 08:03AM  
Feb-13-21 02:41AM  
Jan-28-21 10:44AM  
Jan-06-21 08:07AM  
Dec-30-20 01:42AM  
Dec-16-20 12:32PM  
Dec-09-20 11:30AM  
Nov-15-20 07:50AM  
Nov-11-20 05:44AM  
Nov-09-20 06:35PM  
Nov-02-20 08:03AM  
Oct-28-20 10:33AM  
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
INGENITO GARYChief Medical & Reg. OfficerJun 22Option Exercise4.136,15225,40828,205Jun 23 05:02 PM
INGENITO GARYChief Medical & Reg. OfficerJun 22Sale6.616,15240,64622,053Jun 23 05:02 PM
INGENITO GARYChief Medical & Reg. OfficerJun 21Option Exercise4.13143,848594,092165,901Jun 23 05:02 PM
INGENITO GARYChief Medical & Reg. OfficerJun 21Sale6.59143,848948,67822,053Jun 23 05:02 PM
Tierney David SDirectorMay 20Option Exercise2.5320,00050,600328,207May 24 04:30 PM
Daly Richard JDirectorJan 25Option Exercise3.3550,000167,50052,666Jan 26 05:29 PM
DENKHAUS DONALD ADirectorJan 10Option Exercise2.5340,000101,200317,666Jan 11 06:22 PM
DENKHAUS DONALD ADirectorJan 05Option Exercise3.3550,000167,500277,666Jan 06 04:50 PM
INGENITO GARYChief Medical OfficerDec 07Sale6.993,61225,23722,053Dec 08 05:01 PM
COELHO PHILIP HDirectorAug 26Option Exercise3.1216,66651,998247,768Aug 26 04:45 PM
COELHO PHILIP HDirectorAug 26Sale5.459,54852,042238,220Aug 26 04:45 PM
Miller SteveChief Operating OfficerAug 25Option Exercise3.12120,000374,400821,724Aug 26 04:47 PM
COELHO PHILIP HDirectorAug 25Option Exercise3.1216,66752,001240,600Aug 26 04:45 PM
COELHO PHILIP HDirectorAug 25Sale5.569,49852,809231,102Aug 26 04:45 PM
Miller SteveChief Operating OfficerAug 25Sale5.5680,000444,640741,724Aug 26 04:47 PM
COELHO PHILIP HDirectorAug 24Option Exercise3.1216,66752,001233,427Aug 26 04:45 PM
COELHO PHILIP HDirectorAug 24Sale5.589,49452,929223,933Aug 26 04:45 PM
MCENANY PATRICK JPresident and CEOAug 23Option Exercise3.12120,000374,4004,994,143Aug 24 05:01 PM
MCENANY PATRICK JPresident and CEOAug 23Sale5.6282,617464,7214,911,526Aug 24 05:01 PM
MCENANY PATRICK JPresident and CEOAug 20Option Exercise3.1280,000249,6004,928,304Aug 24 05:01 PM
MCENANY PATRICK JPresident and CEOAug 20Sale5.5254,161298,8604,874,143Aug 24 05:01 PM
GRANDE ALICIAVP, Treasurer and CFOAug 18Option Exercise3.1270,000218,400477,441Aug 19 05:07 PM
GRANDE ALICIAVP, Treasurer and CFOAug 18Sale5.6813,00073,879464,441Aug 19 05:07 PM
GRANDE ALICIAVP, Treasurer and CFOAug 17Option Exercise3.12100,000312,000507,441Aug 19 05:07 PM
GRANDE ALICIAVP, Treasurer and CFOAug 17Sale5.67100,000566,900407,441Aug 19 05:07 PM
O'Keeffe Charles BDirectorAug 16Option Exercise3.1250,000156,000611,709Aug 17 04:55 PM
Tierney David SDirectorAug 13Option Exercise3.1250,000156,000356,874Aug 17 04:48 PM
Miller SteveChief Operating OfficerAug 13Option Exercise3.1265,000202,800742,687Aug 17 04:51 PM
MCENANY PATRICK JPresident and CEOAug 13Option Exercise3.12100,000312,0004,911,019Aug 17 04:53 PM
MCENANY PATRICK JPresident and CEOAug 13Sale6.1262,715384,0654,848,304Aug 17 04:53 PM
Miller SteveChief Operating OfficerAug 13Sale6.0940,963249,416701,724Aug 17 04:51 PM
Tierney David SDirectorAug 13Sale6.0850,000303,895306,874Aug 17 04:48 PM